Query: stroke

Filtered By:
Source: American Heart Journal

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 410 results found since Jan 2013.

Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis and network meta-analysis of randomized trials with 94,283 participants
ConclusionsAll statins showed statistically significant risk reduction of CVD and all-cause mortality in primary prevention populations while increasing the risk for some harm risks. However, the benefit-harm profile differed by statin type. A quantitative assessment of the benefit-harm balance is thus needed since meta-analyses alone are insufficient to inform whether statins provide net benefit.
Source: American Heart Journal - January 11, 2019 Category: Cardiology Source Type: research

Rationale and design for AMPLATZER™ amulet™ left atrial appendage Occluder IDE randomized controlled trial (amulet IDE trial)
Publication date: Available online 21 December 2018Source: American Heart JournalAuthor(s): Dhanunjaya Lakkireddy, Stephan Windecker, David Thaler, Lars Sondergaard, John Carroll, Michael R Gold, Hongfei Guo, Kyle J Brunner, James B Hermiller, Hans-Christoph Diener, Boris Schmidt, Lee MacDonald, Moussa Mansour, Brijeshwar Maini, Joseph LevineAbstractAimsThe Amulet IDE Trial is an ongoing, prospective, randomized, multi-national trial, designed to evaluate the safety and effectiveness of the AMPLATZER™ Amulet™ Left Atrial Appendage Occluder for stroke prevention in comparison to the WATCHMAN Left Atrial Appendage Closur...
Source: American Heart Journal - December 21, 2018 Category: Cardiology Source Type: research

Differences in Statin Utilization and Lipid-Lowering by Race, Ethnicity, and HIV Status in a Real-World Cohort of Persons with Human Immunodeficiency Virus and Uninfected Persons
ConclusionsAmong PWH with statin indication(s), Blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin utilized for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - December 21, 2018 Category: Cardiology Source Type: research

Generalizability of the FOURIER Trial to Routine Clinical Care: Do Trial Participants Represent Patients in Everyday Practice?
ConclusionsOne in seven ASCVD patients in practice would have qualified for FOURIER. The excluded and under-represented populations were at a particularly low or high cardiovascular risk. Statin therapy was under-used and physicians may need to evaluate adherence before adding PCSK9i.
Source: American Heart Journal - December 19, 2018 Category: Cardiology Source Type: research

Yao generalizability of FOURIER to routine practice
ConclusionsOne in seven ASCVD patients in practice would have qualified for FOURIER. The excluded and under-represented populations were at a particularly low or high cardiovascular risk. Statin therapy was under-used and physicians may need to evaluate adherence before adding PCSK9i.
Source: American Heart Journal - December 16, 2018 Category: Cardiology Source Type: research

Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial
ConclusionThe TOMAHAWK trial will address the unresolved issue of timing and general indication of angiography after OHCA without ST-segment elevation.
Source: American Heart Journal - December 12, 2018 Category: Cardiology Source Type: research

Outcomes of Apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
ConclusionsMulti-morbidity is prevalent among the population with AF; efficacy and safety of apixaban is preserved in this subgroup supporting extension of trial results to the most complex AF patients.Clinical trial registrationClinicalTrials.gov (NCT00412984).
Source: American Heart Journal - November 23, 2018 Category: Cardiology Source Type: research

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease – Insights from the STABILITY trial
ConclusionThe primary outcome results of the STABILITY trial were consistent whether using investigator-reported or CEC-adjudicated events. The proportion of investigator-reported events confirmed by CEC varied by type of event. These results should help improve event identification in clinical trials to optimize ascertainment and adjudication.
Source: American Heart Journal - November 8, 2018 Category: Cardiology Source Type: research

Stroke prevention in atrial fibrillation: Closing the gap
Publication date: Available online 25 October 2018Source: American Heart JournalAuthor(s): Sean D. Pokorney, Bernard J. Gersh, Azhar Ahmad, Sana M. Al-Khatib, Melanie Blank, Megan Coylewright, Peter DiBattiste, Jeff S. Healey, Olaf Hedrich, Elaine M. Hylek, Eva Kline-Rogers, Eric D. Peterson, Phil Mendys, Michael J. Mirro, Gerald Naccarelli, Parashar Patel, Christian T. Ruff, Howard Rutman, Norman Stockbridge, Robert Temple
Source: American Heart Journal - October 25, 2018 Category: Cardiology Source Type: research

Rationale and Design of the Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study
Publication date: Available online 29 September 2018Source: American Heart JournalAuthor(s): Aruna D. Pradhan, Nina P. Paynter, Brendan M. Everett, Robert J. Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R. Hiatt, Shun Ishibashi, Wolfgang Koenig, Børge G. Nordestgaard, Jean-Charles Fruchart, Peter Libby, Paul M RidkerAbstractObservational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selective p...
Source: American Heart Journal - October 5, 2018 Category: Cardiology Source Type: research

Risk stratification and clinical outcomes after surgical pulmonary valve replacement
ConclusionPatients undergoing PVR at larger RV volumes had similar survival but more overall CAE. A larger study population with a longer follow-up will be required to determine if early PVR provides survival benefit in the long-term.
Source: American Heart Journal - October 5, 2018 Category: Cardiology Source Type: research

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
ConclusionThe results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.ClinicalTrials.gov identifier: NCT01986881
Source: American Heart Journal - September 6, 2018 Category: Cardiology Source Type: research

EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
Publication date: November 2018Source: American Heart Journal, Volume 205Author(s): Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Chen, Shigeru Saito, Roland Veltkamp, Pascal Vranckx, George D. DangasTranscatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral anticoagulation. In moderate...
Source: American Heart Journal - August 31, 2018 Category: Cardiology Source Type: research

Rationale and design of the EVOLVE short DAPT study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention
ConclusionThe EVOLVE Short DAPT study will prospectively define the safety of DAPT discontinuation at 3 months in high bleeding risk patients treated with the SYNERGY stent.
Source: American Heart Journal - August 17, 2018 Category: Cardiology Source Type: research

A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study
ConclusionsUsing a population-based sample, we derived and validated a tool that predicts the risk of early death and rehospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and rehospitalization for AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes.Graphical AbstractThe Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) Study.
Source: American Heart Journal - July 25, 2018 Category: Cardiology Source Type: research

Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
ConclusionsA bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program
Publication date: September 2018Source: American Heart Journal, Volume 203Author(s): Giorgia Paoli, Maria Francesca Notarangelo, Maria Mattioli, Rachele La Sala, Chiara Foà, Emilia Solinas, Sara Fusco, Cristian Fava, Caterina Caminiti, Giovanna Artioli, Giovanna Pelà, Elisabetta Dall’Aglio, Antonio Manari, Stefano Tondi, Antonio Rizzo, Gaia Trapolin, Giampiero Patrizi, Stefano Cappelli, Giovanni Quinto Villani, Massimo PiepoliAbstractThe main objective of cardiovascular disease prevention is to reduce morbidity and mortality by promoting a healthy lifestyle, reducing risk factors, and improving adherence to medications...
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial
Publication date: August 2018Source: American Heart Journal, Volume 202Author(s): Otavio Berwanger, Jose C. Nicolau, Antonio C. Carvalho, Lixin Jiang, Shaun Goodman, Stephen J. Nicholls, Alexander Parkhomenko, Oleg Averkov, Carlos Tajer, Germán Malaga, Jose F. Kerr Saraiva, Francisco Fonseca, Helio P. Guimaraes, Pedro G.M. de Barros e Silva, Lucas P. Damiani, Denise M. Paisani, Camila M.R. Lasagno, Carolina T. Candido, Nanci Valeis, Diogo D.F. MoiaAbstractBackgroundThe safety and efficacy of ticagrelor in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remain uncertain.Objectives...
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study
ConclusionIn this study, levels of GlycA and hsCRP were independent and additive markers of risk for MACE, death and HF hospitalization.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population
ConclusionsThe burden of AF among Asian patients is increasing. Although the overall risks of cardiovascular events and death following AF onset have decreased over a decade, the event rates are still high. Optimized management of any associated comorbidities should be part of the holistic management approach for patients with AF.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Assessment of left ventricular size and function by 3-dimensional transthoracic echocardiography: Impact of the echocardiography platform and analysis software
ConclusionsThe echocardiography platform and analysis software significantly affect the values of LV parameters obtained by 3DE. Intervendor standardization and improvements in 3DE modalities are needed to broaden the use of LV parameters obtained by 3DE in clinical practice.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial
ConclusionCAMELLIA-TIMI 61 is investigating the safety and efficacy of lorcaserin for MACEs and conversion to diabetes in overweight or obese patients with established cardiovascular disease or multiple cardiovascular risk factors.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale
Publication date: August 2018Source: American Heart Journal, Volume 202Author(s): Shenshen Li, James A. Blumenthal, Chuan Shi, Danielle Millican, Xian Li, Xin Du, Anushka Patel, Pei Gao, Elizabeth Delong, Pallab K. Maulik, Runlin Gao, Xin Yu, Yangfeng WuAbstractDepression and acute coronary syndromes (ACS) are both common public health challenges. Patients with ACS often develop depression, which in turn adversely affects prognosis. Low-cost, sustainable, and effective service models that integrate depression care into the management of ACS patients to reduce depression and improve ACS outcomes are critically needed. Integ...
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention
ConclusionIn a large registry of STEMI patients, manual TA was not associated with lower risk-adjusted in-hospital all-cause mortality compared with PCI-alone regardless of TIT but was associated with significantly greater risk of MACE. In patients with prolonged TIT, manual TA was associated with higher risk-adjusted MACE rates compared with PCI-alone.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT registry®
ConclusionsIn the U.S. the majority of patients were discharged on DAPT following TAVR. Practice patterns varied significantly among hospitals. Patients discharged with DAPT had a similar adjusted risk of mortality, stroke and MI compared to antiplatelet monotherapy, though risk for bleeding was significantly higher. Future investigation is needed to define the optimal antiplatelet therapy for patients undergoing TAVR.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

A clinical decision instrument to predict 30-day death & cardiovascular hospitalizations following an emergency department visit for atrial fibrillation: The atrial fibrillation in the emergency room, part 2 (AFTER2) study
ConclusionsUsing a population-based sample, we derived and validated a tool that predicts the risk of early death and re-hospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and re-hospitalization AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes.Graphical AbstractThe Atrial Fibrillation in the Emergency Room, part 2 (AFTER2) Study
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention
ConclusionIn a large registry of STEMI patients, manual TA was not associated with lower risk-adjusted in-hospital all-cause mortality compared with PCI-alone regardless of TIT but was associated with significantly greater risk of MACE. In patients with prolonged TIT, manual TA was associated with higher risk-adjusted MACE rates compared with PCI-alone.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT registry®
ConclusionsIn the U.S. the majority of patients were discharged on DAPT following TAVR. Practice patterns varied significantly among hospitals. Patients discharged with DAPT had a similar adjusted risk of mortality, stroke and MI compared to antiplatelet monotherapy, though risk for bleeding was significantly higher. Future investigation is needed to define the optimal antiplatelet therapy for patients undergoing TAVR.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research

Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
ConclusionsA bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program
Publication date: September 2018Source: American Heart Journal, Volume 203Author(s): Giorgia Paoli, Maria Francesca Notarangelo, Maria Mattioli, Rachele La Sala, Chiara Foà, Emilia Solinas, Sara Fusco, Cristian Fava, Caterina Caminiti, Giovanna Artioli, Giovanna Pelà, Elisabetta Dall’Aglio, Antonio Manari, Stefano Tondi, Antonio Rizzo, Gaia Trapolin, Giampiero Patrizi, Stefano Cappelli, Giovanni Quinto Villani, Massimo PiepoliAbstractThe main objective of cardiovascular disease prevention is to reduce morbidity and mortality by promoting a healthy lifestyle, reducing risk factors, and improving adherence to medications...
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial
Publication date: August 2018Source: American Heart Journal, Volume 202Author(s): Otavio Berwanger, Jose C. Nicolau, Antonio C. Carvalho, Lixin Jiang, Shaun Goodman, Stephen J. Nicholls, Alexander Parkhomenko, Oleg Averkov, Carlos Tajer, Germán Malaga, Jose F. Kerr Saraiva, Francisco Fonseca, Helio P. Guimaraes, Pedro G.M. de Barros e Silva, Lucas P. Damiani, Denise M. Paisani, Camila M.R. Lasagno, Carolina T. Candido, Nanci Valeis, Diogo D.F. MoiaAbstractBackgroundThe safety and efficacy of ticagrelor in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remain uncertain.Objectives...
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study
ConclusionIn this study, levels of GlycA and hsCRP were independent and additive markers of risk for MACE, death and HF hospitalization.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population
ConclusionsThe burden of AF among Asian patients is increasing. Although the overall risks of cardiovascular events and death following AF onset have decreased over a decade, the event rates are still high. Optimized management of any associated comorbidities should be part of the holistic management approach for patients with AF.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale
Publication date: August 2018Source: American Heart Journal, Volume 202Author(s): Shenshen Li, James A. Blumenthal, Chuan Shi, Danielle Millican, Xian Li, Xin Du, Anushka Patel, Pei Gao, Elizabeth Delong, Pallab K. Maulik, Runlin Gao, Xin Yu, Yangfeng WuAbstractDepression and acute coronary syndromes (ACS) are both common public health challenges. Patients with ACS often develop depression, which in turn adversely affects prognosis. Low-cost, sustainable, and effective service models that integrate depression care into the management of ACS patients to reduce depression and improve ACS outcomes are critically needed. Integ...
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

Assessment of left ventricular size and function by 3-dimensional transthoracic echocardiography: Impact of the echocardiography platform and analysis software
ConclusionsThe echocardiography platform and analysis software significantly affect the values of LV parameters obtained by 3DE. Intervendor standardization and improvements in 3DE modalities are needed to broaden the use of LV parameters obtained by 3DE in clinical practice.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial
ConclusionCAMELLIA-TIMI 61 is investigating the safety and efficacy of lorcaserin for MACEs and conversion to diabetes in overweight or obese patients with established cardiovascular disease or multiple cardiovascular risk factors.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

A clinical decision instrument to predict 30-day death & cardiovascular hospitalizations following an emergency department visit for atrial fibrillation: The atrial fibrillation in the emergency room, part 2 (AFTER2) study
ConclusionsUsing a population-based sample, we derived and validated a tool that predicts the risk of early death and re-hospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and re-hospitalization AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes.Graphical AbstractThe Atrial Fibrillation in the Emergency Room, part 2 (AFTER2) Study
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

Harmony Outcomes: A randomized, double blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—rationale, design, and baseline characteristics
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the GLP-1 RA class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research

Safety and efficacy of non –vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
Conclusions A bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Source: American Heart Journal - July 4, 2018 Category: Cardiology Source Type: research

Assessment of left ventricular size and function by 3-dimensional transthoracic echocardiography: Impact of the echocardiography platform and analysis software
Conclusions The echocardiography platform and analysis software significantly affect the values of LV parameters obtained by 3DE. Intervendor standardization and improvements in 3DE modalities are needed to broaden the use of LV parameters obtained by 3DE in clinical practice.
Source: American Heart Journal - June 21, 2018 Category: Cardiology Source Type: research

I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale
Publication date: August 2018 Source:American Heart Journal, Volume 202 Author(s): Shenshen Li, James A. Blumenthal, Chuan Shi, Danielle Millican, Xian Li, Xin Du, Anushka Patel, Pei Gao, Elizabeth Delong, Pallab K. Maulik, Runlin Gao, Xin Yu, Yangfeng Wu Depression and acute coronary syndromes (ACS) are both common public health challenges. Patients with ACS often develop depression, which in turn adversely affects prognosis. Low-cost, sustainable, and effective service models that integrate depression care into the management of ACS patients to reduce depression and improve ACS outcomes are critically needed. Integratin...
Source: American Heart Journal - June 20, 2018 Category: Cardiology Source Type: research

Atrial fibrillation and stroke: The more we learn, the less we understand
Publication date: July 2018 Source:American Heart Journal, Volume 201 Author(s): Rod Passman
Source: American Heart Journal - June 15, 2018 Category: Cardiology Source Type: research

Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients following percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
Conclusions A bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that rivaroxaban- and dabigatran-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with AF undergoing PCI.
Source: American Heart Journal - June 13, 2018 Category: Cardiology Source Type: research

Harmony Outcomes: A randomized, double blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus —rationale, design, and baseline characteristics
Conclusions Harmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the GLP-1 RA class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - June 13, 2018 Category: Cardiology Source Type: research

A clinical decision instrument to predict 30-day death & amp; cardiovascular hospitalizations following an emergency department visit for atrial fibrillation: The atrial fibrillation in the emergency room, part 2 (AFTER2) study
Conclusions Using a population-based sample, we derived and validated a tool that predicts the risk of early death and re-hospitalization for a cardiovascular reason in emergency department AF patients. The tool can offer information to managing physicians about the risk of death and re-hospitalization AF patients seen in the in emergency department, as well as identify patient groups for future targeted interventions aimed at preventing these outcomes. Graphical abstract
Source: American Heart Journal - June 13, 2018 Category: Cardiology Source Type: research

ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: a multicentre fully nurse-coordinated intensive intervention programme
Publication date: Available online 12 June 2018 Source:American Heart Journal Author(s): Giorgia Paoli, Notarangelo Maria Francesca, Maria Mattioli, Rachele La Sala, Chiara Foà, Emilia Solinas, Sara Fusco, Cristian Fava, Caterina Caminiti, Giovanna Artioli, Giovanna Maria Pelà, Elisabetta Dall’Aglio, Antonio Manari, Stefano Tondi, Antonio Rizzo, Gaia Trapolin, Giampiero Patrizi, Stefano Cappelli, Giovanni Quinto Villani, Massimo Piepoli, Gianni Zobbi, Elisa Nicosia, Diego Ardissino The main objective of cardiovascular disease prevention is to reduce morbidity and mortality by promoting a healthy lifestyle, reducing ri...
Source: American Heart Journal - June 12, 2018 Category: Cardiology Source Type: research

Assessment of left ventricular size and function by three-dimensional transthoracic echocardiography: Impact of the echocardiography platform and analysis software
Conclusions The echocardiography platform and analysis software significantly affects the values of LV parameters obtained by 3DE. Intervendor standardization and improvements in 3DE modalities are needed to broaden the use of LV parameters obtained by 3DE in clinical practice.
Source: American Heart Journal - May 28, 2018 Category: Cardiology Source Type: research

Revival of transcatheter PFO closure: A meta-analysis of randomized controlled trials - impact of shunt size and age
Conclusion According to our meta-analysis TPC plus antiplatelets was superior in terms of stroke prevention when compared to Med-Tx. Furthermore, patients with moderate to severe shunts and those younger than 45 years of age were found to benefit most from TPC.
Source: American Heart Journal - May 26, 2018 Category: Cardiology Source Type: research